Oncology Reviews (Jan 2024)

Metastatic Pancreatic Cancer: Where Are We?

  • Abraham Hernández-Blanquisett,
  • Abraham Hernández-Blanquisett,
  • Valeria Quintero-Carreño,
  • Valeria Quintero-Carreño,
  • María Cristina Martínez-Ávila,
  • María Porto,
  • María Carolina Manzur-Barbur,
  • María Carolina Manzur-Barbur,
  • Emiro Buendía,
  • Emiro Buendía

DOI
https://doi.org/10.3389/or.2023.11364
Journal volume & issue
Vol. 17

Abstract

Read online

Pancreatic cancer is one of the most lethal neoplasms worldwide; it is aggressive in nature and has a poor prognosis. The overall survival rate for pancreatic cancer is low. Most patients present non-specific symptoms in the advanced stages, which generally leads to late diagnosis, at which point there is no option for curative surgery. The treatment of metastatic pancreatic cancer includes systemic therapy, in some cases radiotherapy, and more recently, molecular targeted therapies, which can positively impact cancer control and improve quality of life. This review provides an overview of the molecular landscape of pancreatic cancer based on the most recent literature, as well as current treatment options for patients with metastatic pancreatic cancer.

Keywords